Khyati Niral Shah

Khyati Niral Shah

Auto-generated profile, based on publicly available information

Khyati Niral Shah

Pfizer Inc., South San Francisco, California

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KSKhyati N. Shah
Khyati N. Shah
RBRoma Bhatt
Roma Bhatt
JRJulia Rotow
Julia Rotow
JRJulia Rohrberg
Julia Rohrberg
VOVictor Olivas
Victor Olivas
SBSourav Bandyopadhyay
Sourav Bandyopadhyay

25 June 2018 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
HDHayley J. Donnella
Hayley J. Donnella
JWJames T. Webber
James T. Webber
RLRebecca S. Levin
Rebecca S. Levin
RCRoman Camarda
Roman Camarda
OMOlga Momcilovic
Olga Momcilovic
SBSourav Bandyopadhyay
Sourav Bandyopadhyay

1 November 2015 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
KSKhyati N. Shah
Khyati N. Shah
EWElizabeth A. Wilson
Elizabeth A. Wilson
RMRitu Malla
Ritu Malla
HEHoward L. Elford
Howard L. Elford
JFJesika S. Faridi
Jesika S. Faridi
Tamoxifen is widely used as an adjuvant therapy for patients with estrogen receptor (ERα)–positive tumors. However, the clinical benefit is often limited because of the emergence of drug resistance. In this study, overexpression of ribonucleotide reductase M2 (RRM2) in MCF-7 breast cancer cells resulted in a reduction in the effectiveness of tamoxifen, through downregulation of ERα66 and upregulation of the 36-kDa variant of ER (ERα36). We identified that NF-κB, HIF1α, and MAPK/JNK are the major pathways that are affected by RRM2 overexpression and result in increased NF-κB activity and increased protein levels of EGFR, HER2, IKKs, Bcl-2, RelB, and p50. RRM2-overexpressing cells also exhibited higher migratory and invasive properties. Through time-lapse microscopy and protein profiling studies of tamoxifen-treated MCF-7 and T-47D cells, we have identified that RRM2, along with other key proteins, is altered during the emergence of acquired tamoxifen resistance. Inhibition of RRM2 using siRRM2 or the ribonucleotide reductase (RR) inhibitor didox not only eradicated and effectively prevented the emergence of tamoxifen-resistant populations but also led to the reversal of many of the proteins altered during the process of acquired tamoxifen resistance. Because didox also appears to be a potent inhibitor of NF-κB activation, combining didox with tamoxifen treatment cooperatively reverses ER-α alterations and inhibits NF-κB activation. Finally, inhibition of RRM2 by didox reversed tamoxifen-resistant in vivo tumor growth and decreased in vitro migratory and invasive properties, revealing a beneficial effect of combination therapy that includes RRM2 inhibition to delay or abrogate tamoxifen resistance. Mol Cancer Ther; 14(11); 2411–21. ©2015 AACR.

1 March 2014 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
KSKhyati N. Shah
Khyati N. Shah
KMKshama R. Mehta
Kshama R. Mehta
DPDavid Peterson
David Peterson
MEMarie Evangelista
Marie Evangelista
JLJohn C. Livesey
John C. Livesey
JFJesika S. Faridi
Jesika S. Faridi
Acquired tamoxifen resistance develops in the majority of hormone-responsive breast cancers and frequently involves overexpression of the PI3K/AKT axis. Here, breast cancer cells with elevated endogenous AKT or overexpression of activated AKT exhibited tamoxifen-stimulated cell proliferation and enhanced cell motility. To gain mechanistic insight on AKT-induced endocrine resistance, gene expression profiling was performed to determine the transcripts that are differentially expressed post-tamoxifen therapy under conditions of AKT overexpression. Consistent with the biologic outcome, many of these transcripts function in cell proliferation and cell motility networks and were quantitatively validated in a larger panel of breast cancer cells. Moreover, ribonucleotide reductase M2 (RRM2) was revealed as a key contributor to AKT-induced tamoxifen resistance. Inhibition of RRM2 by RNA interference (RNAi)–mediated approaches significantly reversed the tamoxifen-resistant cell growth, inhibited cell motility, and activated DNA damage and proapoptotic pathways. In addition, treatment of tamoxifen-resistant breast cancer cells with the small molecule RRM inhibitor didox significantly reduced in vitro and in vivo growth. Thus, AKT-expressing breast cancer cells upregulate RRM2 expression, leading to increased DNA repair and protection from tamoxifen-induced apoptosis.

12 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAngel A. Ku
Angel A. Ku
HHHsien-Ming Hu
Hsien-Ming Hu
XZXin Zhao
Xin Zhao
KSKhyati N. Shah
Khyati N. Shah
SKSameera Kongara
Sameera Kongara
SBSourav Bandyopadhyay
Sourav Bandyopadhyay
Synthetic lethal screens have the potential to identify new vulnerabilities incurred by specific cancer mutations but have been hindered by lack of agreement between studies. In the case of KRAS, we identify that published synthetic lethal screen hits significantly overlap at the pathway rather than gene level. Analysis of pathways encoded as protein networks could identify synthetic lethal candidates that are more reproducible than those previously reported. Lack of overlap likely stems from biological rather than technical limitations as most synthetic lethal phenotypes are strongly modulated by changes in cellular conditions or genetic context, the latter determined using a pairwise genetic interaction map that identifies numerous interactions that suppress synthetic lethal effects. Accounting for pathway, cellular and genetic context nominates a DNA repair dependency in KRAS-mutant cells, mediated by a network containing BRCA1. We provide evidence for why most reported synthetic lethals are not reproducible which is addressable using a multi-faceted testing framework.

1 April 2018 in Cell Reports
Verified
Journal Article
Open access
HHHsien-Ming Hu
Hsien-Ming Hu
XZXin Zhao
Xin Zhao
SKSwati Kaushik
Swati Kaushik
LRLilliane Robillard
Lilliane Robillard
ABAntoine Barthelet
Antoine Barthelet
SBSourav Bandyopadhyay
Sourav Bandyopadhyay
Chemotherapy is used to treat most cancer patients, yet our understanding of factors that dictate response and resistance to such drugs remains limited. We report the generation of a quantitative chemical-genetic interaction map in human mammary epithelial cells charting the impact of the knockdown of 625 genes related to cancer and DNA repair on sensitivity to 29 drugs, covering all classes of chemotherapy. This quantitative map is predictive of interactions maintained in other cell lines, identifies DNA-repair factors, predicts cancer cell line responses to therapy, and prioritizes synergistic drug combinations. We identify that ARID1A loss confers resistance to PARP inhibitors in cells and ovarian cancer patients and that loss of GPBP1 causes resistance to cisplatin and PARP inhibitors through the regulation of genes involved in homologous recombination. This map helps navigate patient genomic data and optimize chemotherapeutic regimens by delineating factors involved in the response to specific types of DNA damage.